Zura Bio Limited (NASDAQ:ZURA) Stake Decreased by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC cut its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 44.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,077,251 shares of the company’s stock after selling 1,693,398 shares during the period. Zura Bio accounts for approximately 1.0% of ADAR1 Capital Management LLC’s portfolio, making the stock its 22nd biggest holding. ADAR1 Capital Management LLC’s holdings in Zura Bio were worth $5,193,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ZURA. JPMorgan Chase & Co. increased its stake in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock valued at $6,583,000 after buying an additional 2,611,532 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Zura Bio by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock valued at $2,389,000 after acquiring an additional 42,801 shares in the last quarter. State Street Corp increased its stake in shares of Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after acquiring an additional 127,300 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Zura Bio by 51.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after purchasing an additional 98,972 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Zura Bio in the fourth quarter worth approximately $371,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Trading Down 5.1 %

ZURA stock opened at $1.03 on Monday. The firm has a 50-day moving average of $1.40 and a two-hundred day moving average of $2.63. The firm has a market capitalization of $67.25 million, a PE ratio of -1.94 and a beta of 0.08. Zura Bio Limited has a one year low of $0.97 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter. On average, equities research analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ZURA shares. Oppenheimer reiterated an “outperform” rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Guggenheim reaffirmed a “buy” rating and set a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Chardan Capital lowered their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Finally, HC Wainwright cut their target price on shares of Zura Bio from $5.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.